Translated Titles

The Role of Target Therapy and Immunotherapy in the Treatment of Uveitis




陳彥慈(Yen-Tzu Chen);葉伯廷(Po-Ting Yeh)

Key Words

非感染性葡萄膜炎 ; 單株抗體 ; 免疫調節 ; non-infectious uveitis ; monoclonal antibody ; immunomodulation



Volume or Term/Year and Month of Publication

25卷4期(2021 / 07 / 25)

Page #

512 - 515

Content Language


Chinese Abstract


English Abstract

The management of non-infectious uveitis includes topical and systemic corticosteroid therapy and a variety of immunomodulatory agents. Immunomodulatory monoclonal antibodies are actively researched and may be applied to the treatment of non-infectious uveitis. This essay briefly introduced a few types of immunomodulatory monoclonal antibodies and the results of related clinical studies.

Topic Category 醫藥衛生 > 醫藥衛生綜合
  1. Trivedi A, Katelaris C. The use of biologic agents in the management of uveitis. Intern Med J 2019; 49:1352-63.
  2. Papotto PH, Marengo EB, Sardinha LR, et al. Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev 2014;13:909-16.
  3. Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016;375: 932-43.
  4. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388:1183-92.
  5. Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014;15:14.
  6. Sharma SM, Fu DJ, Xue K. A review of the landscape of targeted immunomodulatory therapies for non-infectious uveitis. Ophthalmol Ther 2018;7:1-17.
  7. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120: 777-87.
  8. Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol 2017;183:71-80.
  9. Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (saril-niu): The phase 2 saturn study. Ophthalmology 2019;126:428-37.
  10. Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology 2016;123: 2413-23.
  11. Caspi RR. Immunotherapy of Uveitis: is gene therapy in our future? in uveitis and immunological disorders, U. Pleyer and C.S. Foster, Editors. Springer Berlin Heidelberg: Berlin, Heidelberg, 2007:193-210.
  12. Nguyen QD, Sadiq MA, Soliman MK, et al. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016;114:T3.